Independent effect of prior exacerbation frequency and disease severity on the risk of future exacerbations of COPD: a retrospective cohort study

Miguel Santibañez Margüello1,9, Roberto Garrastazu2, Mario Ruiz-Nuñez3, Jose Manuel Helguera4, Sandra Arenal5, Cristina Bonnardeux6, Carlos León6, Marc Miravitlles7 and Juan Luis García-Rivero8,9

Few studies have researched the independent effect of COPD severity on the risk of future exacerbations adjusted by previous exacerbation frequency. We aimed to analyse the independent effect of COPD severity on the risk of exacerbations in the following year, and whether this effect was stronger or not than the effect of a previous history of exacerbations. We conducted a retrospective population-based cohort study including 900 patients with confirmed COPD. Exacerbation frequency was observed for the previous year and for the following year. Patients were defined as ‘Frequent Exacerbator’ (FE) phenotype if they suffered \( \geq 2 \) exacerbations in a year, and were categorised according to the severity of COPD (GOLD Grades 1–4). Odds ratios (ORs) were estimated by logistic regression adjusting for age, gender, smoking status, severity of COPD and being FE in previous year. The main predictor of being FE among all grades of COPD severity was a history of frequent exacerbations in the previous year; adjusted OR 4.97; 95% confidence interval (CI) (3.54–6.97). COPD severity was associated with a higher risk of being FE: Crude OR GOLD Grade 4 3.86; 95% CI (1.50–9.93). However, this association diminished after adjusting for being FE in the previous year; adjusted OR 2.08; 95% CI (0.75–5.82). Our results support that a history of frequent exacerbations in the previous year is the most important independent predictor of exacerbations in the following year, also among the most severe COPD patients. Severity of COPD would be associated with a higher risk of exacerbations, but this effect would be partly determined by the exacerbations suffered in the previous year.

**INTRODUCTION**

Chronic obstructive pulmonary disease (COPD) is one of the most common lung conditions observed in clinical practice and the third leading cause of death in the world.\(^1\) The association of COPD and smoking is well established. However, an increasing number of studies have reported a significant prevalence of COPD among non-smokers.\(^2\)-\(^4\)

Exacerbations of COPD are episodes of worsening of symptoms that carry significant consequences for patients,\(^5\)-\(^7\) being responsible for a large proportion of the health-care costs attributable to this prevalent condition.\(^8\) Consequently, their prevention is a key component of COPD-management strategies.\(^9\),\(^10\)

Despite the importance of exacerbations, we know relatively little about their determinants, probably because the heterogeneity of COPD exacerbations reflects their dependence on a complex spectrum of multiple risk factors.\(^5\)

The most consistent predictor of exacerbations appears to be a previous history of exacerbations.\(^11\) This would be supported by new large observational cohort studies such as ‘The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study’,\(^12\) potentially indicating a definable phenotype of exacerbation susceptibility. However, this observational study did not include milder forms of COPD (Mild-GOLD grade 1), nor did it include COPD-confirmed patients without a history of tobacco consumption.

Although exacerbations are generally considered to become more frequent as the severity of the underlying COPD increases,\(^13\) very few studies have researched the independent effect of COPD severity adjusted by a previous history of exacerbations.

We used the data from a retrospective population-based cohort study, including Mild-GOLD grade 1 or Non-smoker patients with confirmed COPD, to test whether a history of frequent exacerbations is the most important predictor of exacerbations in the following year, with independence of disease severity. In addition, we tried to analyse the independent effect of disease severity on the risk of susceptibility to exacerbations.

**RESULTS**

Among 900 patients with confirmed COPD, 194 (21.6%) were women. The overall mean age was 71.2 years (s.d. 11.0), with a mean of years since COPD diagnosis of 6.6 years (s.d. 5.5). In all,

---

1 Preventive Medicine and Public Health Area, Universidad de Cantabria, IDIVAL, Santander, Spain; 2Centro de Salud de Gama, Servicio Cántabro de Salud, Bárcena de Cicero, Spain; 3Centro de Salud de Liérganes, Servicio Cántabro de Salud, Miera, Spain; 4Centro de Salud Bajo Asón, Servicio Cántabro de Salud, Ampuero, Spain; 5Centro de Salud de Suances, Servicio Cántabro de Salud, Suances, Spain; 6Centro de Salud Campoos-Los Valles, Servicio Cántabro de Salud, Mataporquera, Spain; 7Pneumology Department, Hospital Universitari Vall d’Hebron; CIBER of respiratory diseases (CIBERESP), Barcelona, Spain and 8Pneumology Department, Hospital de Laredo, Servicio Cántabro de Salud, Laredo, Spain.

Correspondence: M5 Margüello (santibanezm@unican.es)

Received 12 November 2015; revised 17 May 2016; accepted 6 June 2016
15.7% of the COPD-confirmed patients were never-smokers. The baseline characteristics of the patients are reported in Table 1.

With regard to COPD severity, most of the patients were moderate-GOLD grade 2 (60%); 26.2% were severe-GOLD grade 3; 10.4% were mild-grade 1; and 3.5% were very severe-GOLD grade 4. Twenty eight per cent of the mild-GOLD grade 1 patients developed two or more exacerbations in the following year (‘FE’ phenotype). Incidence of ‘FE’ phenotype increased in our study with increasing disease severity (40%, 42% and 60% among GOLD grades 2, 3 and 4 were ‘FE’ phenotype, respectively).

In all, 85% of our sample was affected by at least one of the studied co-morbidities. The most prevalent co-morbidity was high blood pressure, affecting 60.2% of patients. See Supplementary Table 2.

Table 2 shows the associations between a history of exacerbations and the risk of suffering frequent exacerbations in the following year. Each exacerbation during the past 4 years (range 0–36) increased the risk of being ‘FE’ the next year by 1.20. Each exacerbation during the previous year (range 0–10) increased the risk of being ‘FE’ phenotype the next year by 1.76. As during 4 years the number of exacerbations was approximately four times as high as the number of exacerbations in a single year, this odds ratio (OR) of 1.20 would be equivalent to an average OR per year of 2.07 (2.07 = 1.20^4).

A statistically significant dose–response p trend was obtained after ordinal-categorising the number of exacerbations during 2011 (adjusted linear P trend < 0.001) into 0, 1 and ≥ 2 exacerbations. When categorising into ‘FE’ versus ‘Infrequent

Table 1. Baseline sociodemographic, lifestyle and clinical characteristics of the patients

|                      | IE (N = 568) | FE (N = 332) | Total (N = 900) | P value |
|----------------------|--------------|--------------|----------------|---------|
| **Age, mean [s.d.]** | [69.8 [11.4] | 73.6 [9.8]   | 71.2 [11.0]    | < 0.001 |
| **Gender**           |              |              |                |         |
| Female               | 123 (63.4)   | 71 (36.6)    | 194 (21.6)     | 0.924   |
| Male                 | 445 (63.0)   | 261 (37.0)   | 706 (78.4)     |         |
| **Year since COPD diagnosis, mean [s.d.]** | 6.2 [5.1] | 7.4 [6.1] | 6.6 [5.5] | 0.001 |
| **Smoking**          |              |              |                |         |
| Never-smoker         | 84 (62.2)    | 51 (37.8)    | 135 (15.7)     | 0.001   |
| Former smokers       | 289 (57.9)   | 210 (42.1)   | 499 (57.9)     |         |
| Current smokers      | 166 (72.8)   | 62 (27.2)    | 228 (26.5)     |         |
| Missing values       | 29 (76.3)    | 9 (23.7)     | 38 (4.2)       |         |
| **BMI, mean [s.d.]** | 28.8 [4.7]   | 28.9 [5.3]   | 28.9 [4.9]     | 0.89    |
| Normal weight (18.5–24.9) | 91 (59.9) | 61 (40.1) | 152 (18.8) | 0.396 |
| Overweight (25–29.9) | 198 (63.9)   | 112 (36.1)   | 310 (38.4)     |         |
| Obesity (>30)        | 213 (63.4)   | 123 (36.6)   | 336 (41.6)     |         |
| Underweight (<18.5) | 4 (40)       | 6 (60)       | 10 (1.2)       |         |
| Missing values       | 62 (67.4)    | 30 (32.6)    | 92 (10.2)      |         |
| **BODE-BMI**         |              |              |                |         |
| BMI > 21             | 491 (62.9)   | 290 (37.1)   | 781 (96.7)     | 0.44    |
| BMI ≤ 21             | 15 (55.6)    | 12 (44.4)    | 27 (3.3)       |         |
| Missing values       | 62 (67.4)    | 30 (32.6)    | 92 (10.2)      |         |
| **GOLD Grades (FEV1)** |            |              |                |         |
| Grade 1 (>80%)       | 54 (72)      | 21 (28)      | 75 (10.4)      | 0.029   |
| Grade 2 (>50–80%)    | 259 (59.8)   | 174 (40.2)   | 433 (59.9)     |         |
| Grade 3 (>30–49.9%)  | 110 (57.9)   | 80 (42.1)    | 190 (26.3)     |         |
| Grade 4 (<30%)       | 10 (40)      | 15 (60)      | 25 (3.5)       |         |
| Missing values       | 135 (42)     | 42 (177)     |                |         |
| **History of exacerbations** |        |              |                |         |
| Number of exacerbations in the previous year, mean [s.d.] | 0.92 [1.20] | 2.39 [2.01] | 1.46 [1.71] | < 0.001 |
| Number of exacerbations in the previous 4 years, mean [s.d.] | 3.1 [3.56] | 7.49 [6.32] | 4.72 [5.21] | < 0.001 |
| **Number of exacerbations in the previous year** | | | | |
| None (0 exacerbations) | 275 (84.6) | 50 (15.4) | 325 (36.1) | < 0.001 |
| 1 exacerbation       | 163 (68.3)  | 75 (31.7)   | 238 (26.5)     |         |
| ≥ 2 exacerbations    | 130 (38.6)  | 207 (61.4)  | 337 (37.4)     |         |
| **History of severe exacerbations (hospitalised for exacerbation) in the previous year** | | | | |
| Number of COPD admissions, mean [s.d.] | 0.17 [0.51] | 0.51 [1.03] | 0.29 [0.76] | < 0.001 |
| None (0 COPD admissions) | 497 (68.1) | 233 (31.9) | 730 (81.1) | < 0.001 |
| 1 COPD admission     | 54 (47)     | 61 (53)     | 115 (12.8)     |         |
| ≥ 2 COPD admissions  | 17 (30.9)   | 38 (69.1)   | 55 (6.1)       |         |

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FE, frequent exacerbations in the following year; FEV1, forced expiratory volume in 1 s; IE, infrequent exacerbations in the following year.

*Risk cutoff point for BMI according to BODE index.
Exacerbations’ (IE) phenotype during the previous year, an adjusted Odds Ratio (ORa) of 4.97, 95% CI (3.54–6.97), was obtained with independence of COPD severity.

With respect to the stability of the frequent-exacerbation phenotype over time, among the 563 patients with infrequent exacerbations in the previous year, 438 also had infrequent exacerbations in the following year (negative predictive value, 77.8%). Among the 337 patients with frequent exacerbations in the previous year, there were 207 who had frequent exacerbations in the following year (positive predictive value, 61.4%); 85.5% of patients with frequent exacerbations in the previous year had at least one exacerbation in the following year. Thus, exacerbation frequency in the previous year had a sensitivity of 51.9% and a specificity of 85.8% for the frequency in the following year (see Table 3).

In addition, in Table 3 absolute risk reduction—also called risk difference—is presented. The risk difference was 38% (85.46 per cent—47.42 per cent = 38 per cent). This means that if 100

**Table 2.** Crude and adjusted ORs according to previous exacerbations for the risk of suffering frequent exacerbations in the following year

| History of exacerbations | FE | ORc | 95% CI | ORa | 95% CI |
|--------------------------|----|-----|--------|-----|--------|
| N = 568                  |    |     |        |     |        |
| Number of exacerbations in the previous year (continuous) | — | — | 1.85 | 1.66–2.06 | 1.76 | 1.56–2.00 |
| Number of exacerbations in the previous four years (continuous) | — | — | 1.24 | 1.19–1.30 | 1.20 | 1.15–1.26 |
| Frequent exacerbations in the previous year | — | — | 4.97 | 3.54–6.97 |
| Infrequent exacerbations (<1) | 438 | 125 | 1 | — | 1 | — |
| Frequent exacerbations (≥2) | 130 | 207 | 5.58 | 4.15–7.50 | 4.97 | 3.54–6.97 |
| Number of exacerbations in the previous year | — | — | 1 | — | — |
| None (0 exacerbations) | 275 | 50 | 1 | — | 1 | — |
| 1 exacerbation | 163 | 75 | 2.53 | 1.69–3.80 | 1.86 | 1.18–2.95 |
| ≥ 2 exacerbations | 130 | 207 | 8.76 | 6.03–12.71 | 6.77 | 4.45–10.28 |
| Linear P trend | < 0.001 | < 0.001 |
| History of severe exacerbations (hospitalised for exacerbation) in the previous year | — | — | 1 | — | — |
| Number of COPD admissions (continuous) | — | — | 1.91 | 1.53–2.38 | 1.13 | 0.93–1.37 |
| Frequent severe exacerbations in the previous year | — | — | 1 | — | — |
| None (0 COPD admissions) | 497 | 233 | 1 | — | 1 | — |
| ≥ 1 COPD admissions | 71 | 99 | 2.97 | 2.11–4.19 | 2.13 | 1.45–3.14 |
| Linear P trend | < 0.001 | < 0.001 |

**Table 3.** Stability of the frequent-exacerbation phenotype over time

| Frequent exacerbations in the previous year | 0 | ≥ 1 | Total | Risk (%) | RD (%) | 95% CI | Se (%) | Sp (%) | PV+ (%) | PV− (%) |
|-------------------------------------------|---|----|-------|----------|--------|--------|--------|--------|---------|---------|
| N = 568 | N = 332 | N = 900 |
| Infrequent exacerbations (<1) | 296 | 267 | 563 | 47.42 | 38.04 | 32.45–43.62 | 51.89 | 85.8 | 85.46 | 52.58 |
| Frequent exacerbations (≥2) | 49 | 288 | 337 | 85.46 | 39.22 | 32.99–45.45 | 62.35 | 77.11 | 61.42 | 77.78 |

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; FE, frequent exacerbations in the following year; IE, infrequent exacerbations in the following year; OR, odds ratio; ORc, crude OR; ORa, adjusted OR by age, gender, smoking status and COPD severity (GOLD grades 1–4).
patients were converted from FEIs to infrequent exacerbators, 38% would be prevented from developing an exacerbation in the following year.

COPD severity according to forced expiratory volume in 1 s (FEV1) was associated with a higher risk of being ‘FE’ phenotype in the following year in our crude models: crude OR GOLD grade 4, 3.86; 95% CI (1.50–9.93) (see Table 4). After adjusting for age, gender and smoking status, results remained significant. However, when adding ‘Frequent of exacerbations in the previous year’ to the multivariable model, adjusted \( p \) trend did not yield statistical significance because GOLD grade 3 patients (ORa2 1.38) were not at a higher risk of being ‘FE’ phenotype than GOLD grade 2 patients (ORa2 1.41). Even the crude association for the very severe-GOLD grade 4 patients diminished and did not yield statistical significance: ORa2 2.08; 95% CI (0.75–5.82).

With respect to the remaining sociodemographic (age and gender), lifestyle (tobacco and BMI) and clinical variables (co-morbidities), only age was statistically significantly associated with a higher risk of being ‘FE’ phenotype in the previous year in the multivariable models (see Table 5). None of the studied co-morbidities was an independent predictor of ‘FE’ phenotype. See Supplementary Table 3.

**DISCUSSION**

Main findings

The most important independent predictor of ‘Frequent Exacerbations’ in the following year was the exacerbation frequency during the previous year, with statistically significant dose-response patterns. This effect was independent of COPD severity and main confounders identified in our study. The number of
exacerbations in the previous year is associated simultaneously with the COPD severity and the number of exacerbations in the following year. Thus, a history of exacerbations would be the most important predictor of ‘FE’ phenotype among all grades of disease severity, and even for the most advanced severity grades (very severe-GOLD grade 4) the exacerbations suffered in the past would act as an important intermediate step in the causal pathway of being ‘FE’ phenotype.

Interpretation of findings in relation to previously published work
The importance of prior exacerbation frequency on the risk of future exacerbations is supported by the largest prospective cohort study (ECLIPSE Study)\textsuperscript{12} and numerous additional observational studies,\textsuperscript{14–17} as well as previous large intervention studies.\textsuperscript{18–20}

With regard to COPD severity, some published studies support this rationale to some extent,\textsuperscript{6,12,17,21} but further studies with a higher sample size must focus on the real independent effect of COPD severity on the risk of exacerbation frequency.

In our sample, 10.4% of included patients were GOLD stage 1. In all, 28% of these mild-GOLD stage 1 patients developed two or more exacerbations in the following year (‘FE’ phenotype). These results provide clinical original information with respect to previous studies,\textsuperscript{12,15} supporting the hypothesis that there may therefore be a phenotype of exacerbation susceptibility that includes milder forms of COPD.

Strengths and limitations of this study
One limitation is the retrospective study design based on secondary information available in clinical databases that were not specifically designed with this project in mind. In retrospective studies based on secondary information (records), a main limitation could be the low quality of that information; this could be either because of insufficient completion of medical records or lack of agreement among different records. To minimise any bias, we a priori decided to use only variables in which the data appeared systematically and objectively collected and in which the data appeared internally consistent. Where possible, we obtained agreement by making a comparison between the primary care and hospital records. In addition, it is important to indicate that all included records were checked for valid spirometric results confirming COPD diagnosis.

In some important variables such as FEV\textsubscript{1}, a non-negligible percentage of missing values was obtained (N=177, 19.7%) because the numeric specific value was not registered even though an obstructive spirometry was retrieved from the databases. We performed a sensitivity analysis concerning the effect of missing FEV\textsubscript{1} data. We did so by treating missing values as a separate category and comparing the association between the missing values and the risk of suffering frequent exacerbations in the following year. The missing values showed greater similarity to the reference category (mild-GOLD grade 1) than to the more severe-GOLD grades 2–4. If those missing values were not actually unknown but were mild-GOLD grade 1, similar OR for the remaining GOLD grades 2–4 would have been obtained with a more precise 95% CI. This suggested that the missing data did not unduly bias our findings.

External validity is one of the main limitations regarding clinical trials.\textsuperscript{22,23} This problem can also affect observational studies based on strict inclusion and exclusion criteria.\textsuperscript{24} We checked that our final analysed sample was representative with respect to age, gender and primary health-care centre with respect to the base population. A major strength of our study is that our sample reflected a population-based (real-life) sample, and therefore mild stages and non-smokers with confirmed COPD were identified and included in the random sample. Our prevalence of 15.7% of
confirmed COPD in never-smokers is also supported by published studies."

The fact that information was based on records makes the existence of bias arising from the lack of blindness among patient’s care providers (who treated patients retrospectively blinded to the development of the study) improbable. To minimise a selection bias, only COPD-confirmed cases were chosen, and an attempt to obtain the independent effect of predictors was made in the epidemiological and statistical approach by controlling confounding and stratified analysis.

Implications for future research, policy and practice
Some patients with milder disease (GOLD stages 1) are also subject to frequent exacerbations, suggesting a distinct susceptibility phenotype. This highlights the necessity of reconsidering a more in-depth monitoring and therapeutic and preventive strategies in patients at GOLD grade 1 level classified as ‘FE’ phenotype.

Conclusions
Our study supports the hypothesis that the most important independent predictor of ‘FE’ phenotype in the following year is a history of frequent exacerbations in the previous year, among all grades of COPD severity. Severity of COPD would be associated to a less extent with a higher risk of being ‘FE’ phenotype, and this effect would be in part determined by the exacerbations suffered in the previous year.

MATERIALS AND METHODS
Design and participants
This is a retrospective population-based cohort study. Methods have been described elsewhere. All the patients ≥ 35 years old, with prevalent codes ‘R91’ or ‘R95’ according to the International Classification of Primary Care (ICP), were identified through electronic clinical databases in the province of Cantabria (Northern Spain) on 31 December 2011. The recruitment criteria included no restriction according to a history of tobacco consumption or degree of FEV1 impairment. A total of 9,334 potential COPD patients were identified out of the total population of 362,372 people registered in Cantabria.

A sample of 2,000 patients was obtained by simple random sampling. A comparison of the 2000 sampled patients with respect to the 9,334 potential COPD patients, on basic sociodemographics, is presented in Supplementary Table 1. Spirometric data were carefully revised for each of these patients. COPD diagnosis was considered as confirmed if a spirometry with bronchodilatation test consistent with obstructive disease (defined as a FEV1/forced vital capacity ratio of < 0.7) was retrieved from the databases, and it was rejected if spirometry was not consistent with obstructive disease. Diagnosis of COPD was confirmed in 900 patients (45.3%), rejected in 197 patients (9.9%) and not confirmed—not rejected in the remaining patients (44.8%). Final analysis was restricted to COPD-confirmed patients. The flow chart for selecting study patients is shown in Figure 1.

Data sources and variables
Data for each patient were individually gathered from primary care medical electronic medical records (OMI-AP) and complemented with hospital electronic records (eVISOR), which contain information about medical admissions. Clinical and demographic characteristics of all patients were recorded, including age, years since diagnosis of COPD, treatments and vaccinations, smoking status, alcohol consumption and co-morbidities. Records of diagnoses of selected co-morbidities, including diabetes, osteoporosis, atrial fibrillation, ischaemic heart disease, heart failure and high blood pressure, occurring before the start of the study, were retrieved from the database.

Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both; moderate exacerbations) or that led to hospitalisation (severe exacerbations). This case definition therefore met the criteria for a definition of health-care utilisation. Exacerbation frequency was observed for the previous year (2011), the previous four years (2008–2011) and for the following year (2012). We also defined frequent exacerbations (‘FE’ phenotype) as two or more exacerbations in a year, because this definition coincides with current health-care utilisation criteria for frequent exacerbations.

Statistical analyses
Discrete variables were expressed as counts (percentage) and continuous variables as mean (s.d.). Statistical differences between groups were assessed with the χ2-test or Fisher’s exact test, when appropriate, for categorical variables. The Student’s t-test was used for the continuous variables.

Exacerbation frequency (both moderate and severe exacerbations) for the following year (2012) was treated as a dichotomous dependent variable in the regression models: ‘FE’ phenotype versus ‘Infrequent Exacerbator’ (IE) phenotype (none or one exacerbation).

Exacerbation frequencies (‘during the previous year (2011)’ and ‘during the last four years (2008–2011)’ were treated as independent variables and included as continuous variables in the regression models.

Exacerbation frequency (‘during the previous year (2011)’ was also ordinal-categorised as ‘0 exacerbations’, ‘1 exacerbation’ and ‘≥ 2 exacerbations’. Next, the ‘0’ and ‘1’ categories were combined, and thus a dichotomous variable ‘FE’ versus ‘IE’ phenotype in the previous year was obtained.

Patients were also ordinal-categorised into 4 categories of severity of COPD according to FEV1 quantitative results, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD grades 1-4). Last, FEV1 was transformed in an ordinal scale according to per 5% decrease in per cent of predicted value.

Crude and adjusted ORs with their 95% CI were estimated by unconditional logistic regression, adjusting for age (continuous), gender, smoking status (no smoker, former smoker, current smoker), severity of COPD (ordinal GOLD grades 1-4) and ‘FE’ phenotype (yes/no) in the previous year.

Tests for OR trends were calculated for the ordinal independent variables using logistic models that included categorical terms as continuous variables. For these trend tests, we used the likelihood ratio test.

The final sample size (n = 900) would have sufficient power (1 – β > 90%) to detect relative risks ≥ 1.16 as significant for a 50% risk of the effect in the unexposed, considering an unexposed/exposed ratio of 1, using a two-tailed χ2-test with an α level < 0.05.

To assess the stability of the frequent-exacerbation phenotype over time, we calculate positive and negative predictive values, sensitivity and specificity. As impact measure, the absolute risk reduction, also called risk difference, was estimated.

The α error was set at 0.05, and all P values were bilateral. All statistical analyses were conducted using IBM SPSS Statistics version 22.0.

Approval of the research protocol was obtained from the Clinical Research Ethics Committee of Cantabria before the acquisition of data. Patient records/information was anonymised and de-identified before analysis.

ACKNOWLEDGEMENTS
We thank the Cantabrian Health Service for their support for the study.

CONTRIBUTIONS
M.S.M., R.G., J.M.H., S.A. and J.L.G-R. contributed to the conception and design of the study. M.S. and R.G. performed statistical analysis. M.S. drafted the manuscript. R.G., J.M.H., M.R.N. S.A., and C.B. and C.L. contributed to acquisition of the data, analysis and interpretation of the data, revised the manuscript, critically contributing to important intellectual content and gave the final approval for publication. J.L.G-R. supervised the analysis, was involved in drafting the manuscript and gave final approval of the version to be published. M.M. was involved in drafting the manuscript, revised it critically contributing to important intellectual content and gave the final approval for publication.
COMPETING INTERESTS

J.L.G.R. reports receiving consulting and/or speaking fees from Almirall, Boehringer Ingelheim, Pfizer, Astra Zeneca, Chiesi, GlaxoSmithKline, Menarini, Takeda, Teva and Ferrer y Novartis; J.M.H. reports receiving speaking fees from GlaxoSmithKline, Boehringer, Novartis, Mundipharma and y Astra Zeneca; C.B. reports receiving speaking fees from GlaxoSmithKline, Boehringer, Ferrer, Astra Zeneca and Teva, y Chiesi; M.M. reports receiving consulting and/or speaking fees from Almirall, AstraZeneca, Boehringer Ingelheim, Ferrer Group, GlaxoSmithKline, Grifols, Esteve, Pfizer, Teva, Cipla, Novartis and Gebo Pharma y Takeda. The remaining authors declare no conflict of interest.

FUNDING

The authors declare that no funding was received.

REFERENCES

1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).
2. Zhou, Y. et al. COPD in Chinese nonsmokers. Eur. Respir. J. 33, 509–518 (2009).
3. Shintcliffe, P. et al. COPD prevalence in a random population survey: a matter of definition. Eur. Respir. J. 30, 232–239 (2007).
4. Menezes, A. M. et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 366, 1875–1881 (2005).
5. Wedzicha, J. A., Brill, S. E., Allinson, J. P. & Donaldson, G. C. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 11, 181 (2013).
6. Miravitlles, M. et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59(Suppl 5), 387–395 (2004).
7. Seemungal, T. A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157(Suppl 5), 1418–1422 (1998).
8. Sullivan, S. D., Ramsey, S. D. & Lee, T. A. The economic burden of COPD. Chest 117 (Suppl 2), 55–92 (2000).
9. Miravitlles, M. et al. Spanish Guideline for COPD (GesEPOC). Update 2014. Arch. Bronconeumol. 50(Suppl 1), 1–16 (2014).
10. Celli, B. R. & MacNee, W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23, 932–946 (2004).
11. Donaldson, G. C. & Wedzicha, J.A. COPD exacerbations 1: Epidemiology. Thorax 61, 164–168 (2006).
12. Hurst, J. R. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363, 1128–1138 (2010).
13. Hoogendoorn, M., Feenstra, T. L., Hoogenveen, R. T., Al, M. & Mølken, M. R. Association between lung function and exacerbation frequency in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 5, 435–444 (2010).
14. Mullerova, H., Shukla, A., Hawkins, A. & Quint, J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open 4, e006171 (2014).
15. Huseba, G. R. et al. Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study. PLoS ONE 9, e109721 (2014).
16. Bowler, R. P. et al. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 146(Suppl 4), 941–950 (2014).

17. Yang, H. et al. Predictors of exacerbation frequency in chronic obstructive pulmonary disease. Eur. J. Med. Res. 19, 18 (2014).
18. Albert, R. K. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365, 689–698 (2011).
19. Tashkin, D. P. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543–1554 (2008).
20. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775–789 (2007).
21. Miravitlles, M. et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 67, 495–501 (2000).
22. Glasgow, R. E., Magid, D. J., Beck, A., Ritzwoller, D. & Estabrooks, P. A. Practical clinical trials for translating research to practice: design and measurement recommendations. Med. Care 43, 551–557 (2005).
23. Julian, D. G. & Pocock, S. J. Interpreting a Trial Report (WB Sanders, 1997).
24. Persaud, N. & Mamdani, M. M. External validity: the neglected dimension in evidence rankings. J. Eval. Clin. Pract. 12, 450–453 (2006).
25. Garrastazu, R. et al. Prevalence of influenza vaccination in chronic obstructive pulmonary disease patients and impact on the risk of severe exacerbations. Arch. Bronconeumol. 52, 88–95 (2015).
26. Hofmans-Ookses, I. M. & Lamberts, H. The International Classification of Primary Care (ICPC): new applications in research and computer-based patient records in family practice. Fam. Pract. 13, 294–302 (1996).
27. Santibáñez, M., Paz-Zalueta, M., Ruiz, M., Castro, I. & Llorca, J. Factors associated with lack of adherence to antenatal care in African immigrant women and Spanish women in northern Spain: the role of social risk factors in combination with language proficiency. Midwifery (Suppl 1), 61–67 (2015).
28. Rubio Gil, E. et al. [Quality of records in OMI-AP of the patients with stroke followed in primary care]. Rev. Cardíol. Asist. 25(Suppl 6), 341–347 (2010).
29. de Burgos, C., Novo, S., Llorente, E. & Salmeron, M. A. Study of prescription-indication of proton pump inhibitors. Rev. Clin. Esp. 206(Suppl 6), 266–270 (2006).
30. Divo, M. et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 186, 155–161 (2012).
31. de Miguel-Diez, J., Garcia, T. G. & Maestu, L. P. Comorbidities in COPD. Arch. Bronconeumol. 46(Suppl 11), 20–25 (2010).
32. Wedzicha, J. A. & Seemungal, T. A. R. COPD exacerbations: defining their cause and prevention. Lancet 370, 786–796 (2007).
33. Burge, S. & Wedzicha, J. A. COPD exacerbations: definitions and classifications. Eur. Respir. J. Suppl 41, 46s–53s (2003).
34. Vestbo, J. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 187, 347–365 (2013).

The work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Supplementary Information accompanies the paper on the npj Primary Care Respiratory Medicine website (http://www.nature.com/npjpcrm)